FOOTPRINT-CAFÉS
21.4.2016 08:01:21 CEST | Business Wire | Press release
Footprint Cafés, a new chain of sustainable enterprise cafés that will re-invest 100% of net profits into local communities has launched today. The brainchild of Georgina Hemmingway, a graduate of the Judge Business School at the University of Cambridge, Footprint Cafés has also attracted the personal endorsement and financial support of Horizon Discovery Group plc CEO, angel investor and enterprise champion, Dr. Darrin M. Disley who was honoured in the Queen’s Birthday Honours today with a Queen’s Award for Enterprise Promotion.
Footprint Cafés aims to establish itself in every corner of the world, becoming the brand for ethically-motivated tourists, giving them an authentic local experience combined with world class standards. Over the past two year Georgina has already proved the business model works with the success of New Leaf Book café in Siem Reap, Cambodia and is now expanding the concept to the cultural city of Battambang, Cambodia. Darrin Disley, who has become a trustee of the charity, has pledged an initial $150,000 cornerstone donation to a fundraising campaign that aims to raise $1 million by 2017.
Dr. Darrin M. Disley, winner of the Queen’s Award for Enterprise Promotion, commented, “I am delighted to be supporting such a uniquely pure and socially impactful project. Georgina’s idea for Footprint Cafés originated at the Judge Business School and it is fantastic to have been part of her journey and see this come to fruition today.
“Ethical entrepreneurship is at the heart of everything I do and is also a quality which is essential for the development of any successful and sustainable growth business. I am grateful not only to be receiving recognition for the work that I have done, but also to be able support Footprint Cafés mission of addressing global illiteracy, gender inequality and local community development, one fantastic Enterprise Café at a time.”
Footprint Cafés has also launched today a second hand book donation drive. Footprint Cafés will send your donated books to Cambodia, donating any children’s books to rural schools and selling all fiction books in their cafes as holiday reads for tourists. All money raised from book sales in the cafes will be given to the local community as grants for educational projects.
Georgina Hemmingway, Founder of Footprint Cafés, added: “Tourism is one of the fastest growing sectors in the world, and it also represents a significant opportunity to connect and empower local communities. At the moment that opportunity is often wasted with profits being drained off-shore to wealthy owners. Footprint Cafes will connect the global to the local by harnessing the spending power of tourism as a force for local change and empowerment one amazing café at a time.”
-Ends-
About the book drive
Footprint Cafes needs previously loved fiction and children’s books. Individuals are encouraged to write messages inside the books to the unknown Footprint customer. Individuals who would like to donate to the drive are asked to write to Footprint cafes directly to organise collection.
Contact info@footprintcafes.org for details on how to donate your books.
About Footprint Cafés – www.footprintcafes.org
Footprint Cafés is a triple-lock social enterprise that is undertaking an audacious but achievable mission of building a chain of sustainable Enterprise Cafés that break down barriers to education and deliver impacting change to local communities.
Founded by Georgina Hemmingway the enterprise builds on the success of over the past three years New Leaf Book café in Siem Reap, Cambodia which now employs 17 staff and has generated and donated its profits to eight local organisations tackling illiteracy, gender inequality and community development
The expansion of the model into the cultural city of Battambang, Cambodia supported by the first phase of a $1 million fund-raising drive has already begun with further plans to expand through Indochina and beyond,
About Dr. Darrin M. Disley’s Queens Award
Dr. Darrin M. Disley is the co-founder and Chief Executive Officer of Horizon Discovery Group plc, a successful UK listed life science company based in Cambridge. Dr Disley has made a major contribution to raising the profile of life sciences both in Cambridge and beyond.
As part of his endeavours, he has concentrated on a voluntary programme to raise the profile of entrepreneurship and its connection with life sciences. He has given many hours of time to aid young entrepreneurs through mentoring and speaking engagements. In the past four years, over 100 young entrepreneurs have benefited from his advice, time and financial support and almost a dozen businesses have been launched, raising over ten million pounds in capital. He remains an advisor to many of them.
Darrin also provides assistance to several social enterprises, students from underprivileged backgrounds and advises and assists two universities along with Cambridge University Entrepreneurs.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160420006628/en/
Contact:
For Media Enquiries
Consilium Strategic Communications
Amber
Fennell, Jessica Hodgson, Matthew Neal
Fennell@consilium-comms.com
Tel:
+44 (0) 203 709 5700
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom